From August 16, 2023 to September 30, 2023, the company has repurchased 400,000 shares, representing 0.51% for CNY 22.64 million. With this, the company has completed the repurchase of 400,000 shares, representing 0.51% for CNY 22.64 million under the buyback announced on August 17, 2023.
Hangzhou Alltest Biotech Co., Ltd.
Equities
688606
CNE1000053G6
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
51.76 CNY | -0.08% | -10.36% | -24.55% |
Apr. 29 | China, HK stocks rise, led by property shares | RE |
Apr. 26 | Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-24.55% | 554M | |
-6.76% | 11.98B | |
-5.68% | 8B | |
+8.91% | 5.85B | |
+28.87% | 5.54B | |
-15.84% | 3.84B | |
+10.70% | 2.66B | |
-60.92% | 2.62B | |
-6.99% | 2.33B | |
+15.67% | 2B |
- Stock Market
- Equities
- 688606 Stock
- News Hangzhou Alltest Biotech Co., Ltd.
- Tranche Update on Hangzhou Alltest Biotech Co., Ltd.'s Equity Buyback Plan announced on August 17, 2023.